IPO Listed — 29 May 2026
Listing Price: ₹452
Q-Line Biotech SME IPO GMP History | Listing Price ₹452 & Kostak Rate
Q-Line Biotech SME IPO has been listed on May 29, 2026 at a listing price of ₹452, against the issue price of ₹343 — a gain of ₹109 (+31.78%). The GMP peaked at ₹140 on 21 May 2026 and reached a low of ₹42 on 18 May 2026. The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Q-Line Biotech SME IPO raised ₹251 Cr. through its IPO at a price band of ₹326 to ₹343 per share, with a lot size of 400 shares. The IPO was open for subscription from 21 May 2026 to 25 May 2026.
GMP Trend Chart
Day-wise GMP Trend
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| 27 May 2026 | ₹ 108 | 31% | ₹ 0 | ₹ 0 | |
| 26 May 2026 | ₹ 99 | 29% | ₹ 0 | ₹ 0 | |
| 25 May 2026 | ₹ 126 | 37% | ₹ 0 | ₹ 0 | |
| 23 May 2026 | ₹ 130 | 38% | ₹ 0 | ₹ 0 | |
| 22 May 2026 | ₹ 120 | 35% | ₹ 0 | ₹ 0 | |
| 21 May 2026 | ₹ 140 | 41% | ₹ 0 | ₹ 0 | |
| 20 May 2026 | ₹ 110 | 32% | ₹ 800 | ₹ 0 | |
| 19 May 2026 | ₹ 69 | 20% | ₹ 800 | ₹ 0 | |
| 18 May 2026 | ₹ 42 | 12% | ₹ 0 | ₹ 0 |
Q-Line Biotech SME IPO Dates
| Event | Date |
|---|---|
| Open Date | 21 May, 2026 |
| Close Date | 25 May, 2026 |
| Allotment Date | 26 May, 2026 |
| Refund Date | 27 May, 2026 |
| Credit to Demat | 27 May, 2026 |
| Listing Date | 29 May, 2026 |
Q-Line Biotech SME IPO Actual Listing Price
| Basis | Value |
|---|---|
| Issue Price | ₹343 |
| GMP-Based Estimate (Pre-Listing) | ₹451 (+31.5%) |
| Actual Listing Price | ₹452 (+31.78%) |
| Listing Gain / Loss | +₹109 per share |
| Listing Date | 29 May, 2026 |
Is Q-Line Biotech SME IPO GMP Reliable?
Grey market premium for Q-Line Biotech SME IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- Cross-check before acting: Review the Q-Line Biotech SME IPO full review for a fundamentals-based assessment before making any grey market trades.
Q-Line Biotech SME IPO IPO Kostak Rate Explained
The Kostak rate for Q-Line Biotech SME IPO was not active during the subscription period, as no grey market premium was established. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not active for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Q-Line Biotech SME IPO
The company is promoted by Saurabh Garg along with Amita Garg and other promoter group members. Q-Line Biotech follows a business model focused on indigenous manufacturing, imports, distribution, and after-sales support for diagnostic instruments and consumables. The company emphasises affordable healthcare solutions under the “Make in India” initiative while investing in research, quality control, and technology-driven manufacturing to strengthen its position in the Indian diagnostic industry.
Strengths & Risks
Strengths
- ✓ Strong presence in the diagnostic and IVD products industry across India.
- ✓ Wide product portfolio including biochemistry, molecular diagnostics, ELISA, and rapid test kits.
- ✓ Focus on indigenous manufacturing under the “Make in India” initiative.
- ✓ Experienced promoter leadership with healthcare industry expertise and nationwide distribution network.
- ✓ Strong emphasis on R&D, quality standards, and ISO-certified manufacturing processes.
Risks
- ⚠ Business depends heavily on the healthcare and diagnostics sector demand cycle.
- ⚠ High competition from established multinational diagnostic and medical device companies.
- ⚠ Regulatory changes in medical devices and diagnostic products may impact operations.
- ⚠ Dependence on continuous innovation and new product approvals for growth.
- ⚠ Any disruption in raw material supply or distributor network can affect business performance.
Frequently Asked Questions about Q-Line Biotech SME IPO
What is the GMP of Q-Line Biotech SME IPO?
The current Grey Market Premium (GMP) of Q-Line Biotech SME IPO is ₹ 108.
What is the Kostak Price of Q-Line Biotech SME IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Q-Line Biotech SME IPO is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What is the Subject to Sauda Price of Q-Line Biotech SME IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is : Retail: ₹ 0, SHNI: ₹ 0, BHNI: ₹ 0.
What was the actual listing price of Q-Line Biotech SME IPO?
Q-Line Biotech SME IPO listed on May 29, 2026 at ₹452, against the issue price of ₹343 — a gain of +31.78%.
How did the GMP of Q-Line Biotech SME IPO trend before listing?
The GMP of Q-Line Biotech SME IPO was rising in its final days before listing. The GMP peaked at ₹140 on 21 May 2026. View the day-wise table above for the complete GMP history.
Explore Q-Line Biotech SME IPO Further
For a complete picture before making your investment decision, explore these resources:
Discussion 0
No comments yet
Be the first to share your thoughts!